Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$486.62 USD

486.62
729,759

+1.86 (0.38%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $487.17 +0.55 (0.11%) 6:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (50 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Paragon 28 (FNA) Expands SMART 28 Ecosystem With New Launches

Paragon 28 (FNA) strengthens its position in the foot and ankle device market with the launch of the SMART28 Case Management Portal and the SMART Bun-Yo-Matic device.

Compelling Reasons to Hold Molina Healthcare (MOH) Stock Now

Molina Healthcare (MOH) remains well-poised for growth, attributable to membership growth in Medicaid and Medicare businesses. Buyouts and an adequate cash balance remain other benefits.

Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio Now

Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.

Haemonetics (HAE) Set to Launch VASCADE MVP XL in US

Haemonetics (HAE) expands its VASCADE portfolio with the full market release of the VASCADE MVP XL vascular closure device in the U.S. market.

Accuray's (ARAY) Radixact for Cancer Treatment Debuts in US

Accuray's (ARAY) Radixact System with VitalHold technology is set to enhance precision and comfort in radiation therapy.

Is Intuitive Surgical (ISRG) a Buy as Wall Street Analysts Look Optimistic?

Based on the average brokerage recommendation (ABR), Intuitive Surgical (ISRG) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Stereotaxis (STXS) Achieves CE Mark in Europe for GenesisX

Stereotaxis (STXS) gets a CE mark in Europe for its GenesisX robotic system. Following this, the company also submits a 501(k) application for FDA clearance.

Sanghamitra Saha headshot

Inflation Cools in July: 4 Sector ETFs & Stocks to Thrive

The annual inflation rate in the United States slowed for a fourth successive month in July 2024.

Labcorp (LH) Gains From New Collaborations Amid FX Issues

Labcorp's (LH) Biopharma Laboratory Services business is benefiting from collaborations with leading pharmaceutical and biotechnology companies.

Accelerate Diagnostics (AXDX) Completes WAVE Pre-Clinical Trial

Accelerate Diagnostics (AXDX) is confident about WAVE product design and the system's capabilities after the successful completion of the pre-clinical trial.

Here is What to Know Beyond Why Intuitive Surgical, Inc. (ISRG) is a Trending Stock

Zacks.com users have recently been watching Intuitive Surgical (ISRG) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Neuronetics (STIM) Inks a New Merger Agreement With Greenbrook

Neuronetics (STIM) signs a merger agreement with Greenbrook to acquire all its outstanding shares. The transaction is expected to be closed during the fourth quarter of 2024.

Can Intuitive Surgical (ISRG) Run Higher on Rising Earnings Estimates?

Intuitive Surgical (ISRG) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Quest Diagnostics (DGX) Gains From Innovation, Customer Wins

A key driver in Brain Health growth is Quest Diagnostics' (DGX) Alzheimer's disease portfolio, featuring the AD-Detect blood testing services and the CSF Tests for diagnosing and monitoring.

Neuronetics (STIM) Q2 Loss Wider Than Expected, Revenues Fall Y/Y

Neuronetics' (STIM) second-quarter 2024 top-line results reflect lower revenues from NeuroStar Advanced Therapy System and Treatment sessions.

Here's How Much a $1000 Investment in Intuitive Surgical, Inc. Made 10 Years Ago Would Be Worth Today

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Illumina (ILMN) Beats on Q2 Earnings, Lowers 2024 Sales View

Illumina's (ILMN) Q2 earnings and revenues surpass estimates in a challenging global macroeconomic environment.

Haemonetics (HAE) Q1 Earnings Miss Estimates, Gross Margin Rises

Haemonetics' (HAE) earnings lag estimates in the first quarter of fiscal 2025. However, the company remains confident about its strategy for sustained profitable growth.

Prestige Consumer's (PBH) Q1 Earnings Beat, Margins Shrink

Prestige Consumer (PBH) first-quarter sales bear the brunt of the ongoing supply chain challenges in the Clear Eyes business.

Insulet (PODD) Q2 Earnings Miss Estimates, '24 Sales View Raised

Insulet's (PODD) second-quarter performance benefits from the continued high demand for Omnipod 5.

Envista (NVST) Q2 Earnings & Revenues Miss, Margins Fall

Envista's (NVST) Spark division sales witness a slowdown in the second quarter due to the deferment of a larger portion of case revenues.

Veracyte (VCYT) Q2 Earnings Beat Estimates, '24 Sales View Up

Veracyte's (VCYT) second-quarter 2024 performance reflects the strength of its testing business.

National Vision (EYE) Tops Q2 Earnings, Lowers '24 Outlook

National Vision (EYE) delivers an earnings beat in the second quarter of 2024 and announces new transformative actions for long-term growth.

Myriad Genetics (MYGN) Q2 Earnings Surpass, '24 Outlook Raised

Myriad Genetics (MYGN) delivers a strong performance across its portfolio in the second quarter of 2024 and increases its long-term revenue growth rate target.

Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Down

Charles River's (CRL) Manufacturing business segments report organic revenue growth, partially offset by lower revenues in the DSA and RMS segments.